A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 12 Jan 2023 Status changed from active, no longer recruiting to completed.
- 29 Dec 2022 This trial has been completed in Poland , according to European Clinical Trials Database record
- 07 Jul 2022 This trial has been completed in Ireland, according to European Clinical Trials Database record